4.1.5 Sinopharm

The Beijing Institute of Biological Products developed the Sinopharm COVID-19 vaccine. Clinical trials were conducted in UAE and Bahrain, and the vaccine proved to have an efficacy of approximately 78.1% against mild cases and 100% against severe cases. 

Sinopharm has been used in vaccination campaigns across several countries in Asia, Africa, Europe, and South America. It is administered by intramuscular injection into the deltoid muscle. 

For complete immunization, at least two doses of the Sinopharm vaccine are required, with an interval of 3-4 weeks between doses, as recommended by the World Health Organization (WHO). 

Notify of
0 Discussions
Inline Feedbacks
View all comments
Post a comment

Leave a Comment

Your email address will not be published. Required fields are marked *

Would love your thoughts, please comment.x